Asset Details
Do you wish to reserve the book?
Regulatory T cell therapies: from patient data to biological insights
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Regulatory T cell therapies: from patient data to biological insights
Do you wish to request the book?
Regulatory T cell therapies: from patient data to biological insights
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Regulatory T cell therapies: from patient data to biological insights
2025
Overview
Regulatory T cell (Treg) therapies are emerging as powerful tools for treating autoimmune and inflammatory diseases, preventing graft-versus-host disease (GvHD), and promoting organ transplant tolerance. Building on the identification of chimeric antigen receptor (CAR)-expressing Tregs as a correlate of poor patient outcomes in CD19-CAR T cell therapy, this review examines strategies for learning from clinical samples and data to improve Treg therapies. We highlight current and next-generation Treg modalities, including polyclonal, antigen-specific, converted, TCR-engineered, and CAR-engineered Tregs, provide a comprehensive overview of Treg clinical trials, and evaluate the evolving toolkit for in vivo Treg monitoring. Emphasis is placed on advanced immunomonitoring technologies, such as single-cell multi-omic profiling, epigenetic analysis, and spatial transcriptomics, which enable precise characterization of Treg persistence, function, and lineage stability. By integrating insights from adoptive T cell therapies and cutting-edge multi-omic platforms, this review outlines how Treg therapies can be optimized as “living drugs” capable of establishing immune tolerance across diverse clinical contexts.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Animals
/ Antigens
/ Diabetes
/ Graft vs Host Disease - immunology
/ Graft vs Host Disease - prevention & control
/ GvHD
/ Humans
/ Immunotherapy, Adoptive - methods
/ Patients
/ Receptors, Chimeric Antigen - genetics
/ Receptors, Chimeric Antigen - immunology
/ T-Lymphocytes, Regulatory - immunology
/ T-Lymphocytes, Regulatory - metabolism
/ T-Lymphocytes, Regulatory - transplantation
/ Treg
